Company Profile

Viropharma Inc
Profile last edited on: 6/15/21      CAGE: 44SP4      UEI: MGHZQ16KEN33

Business Identifier: Small-molecule therapeutics for RNA virus-caused diseases: antivir
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

730 Stockton Drive
Exton, PA 19341
   (610) 458-7300
Location: Single
Congr. District: 06
County: Chester

Public Profile

In November 2013, Viropharma was acquired by Shire PLC. News reports at the time suggested that that purchase was primarily due to SHire's decision to acquire the orphan drug Cinryze, a drug developed by Viropharma for the inflammatory condition hereditary angioedema, and which complemented Shire’s Firazyr for the same malady. Involved in SBIR from soon after its founding in 1994, ViroPharma is a development stage pharmaceutical company committed to the commercialization, development and discovery of new antiviral medicines. Its current drug development and discovery activities are focused on a number of ribonucleic acid (RNA) virus diseases, including viral meningitis, viral respiratory infection, the common cold, respiratory syncytial virus pneumonia and hepatitis C. ViroPharma's most advanced product candidate, pleconaril, is being developed for the treatment of common RNA virus diseases. ViroPharma has completed a Phase II challenge study in viral respiratory infection (VRI) with pleconaril, in which all evaluated disease measures were significantly reduced in treated subjects, along with another Phase II clinical trial for viral meningitis which demonstrated that pleconaril significantly reduced disease duration

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1996 1 NIH $100,000
Project Title: Hepatitis C Virus RNA Helicase Genotypes
1995 1 NIH $90,813
Project Title: Drug Screening Assay for Hepatitis C Virus RNA Helicase

Key People / Management

  Michel De Rosen -- President

  Marc S Collett

  James M Groarke

  Robert Jordan

  Vincent J Milano -- Chief Executive Officer

  Claude H Nash -- Founder; Chief Executive Officer; Chairman

  Charles A Rowland Jr -- Vice President; Chief Financial Officer

  Daniel B Soland -- Chief Operating Officer